1 Oncoprotein 18 is necessary for malignant cell proliferation in bladder 2 cancer cells and serves as a G3-specific non-invasive diagnostic marker 3 candidate in urinary RNA 4 5 Merle 20 21 running head: OP18-based tumor diagnostics and biology 22 Keywords: liquid biopsy; uroplakin 1A; siRNA; ECV-304; RT-4; theranostics; 23 RNA marker; drug target 25 ABSTRACT 26 Background: 27 Urine-based diagnostics indicated involvement of OP18 in bladder cancer. In cell 28 culture models we investigated the role of oncoprotein 18 for malignant cell 29 growth. 30 Methods: 31 We analyzed 113 urine samples and investigated two human BCa cell lines as a 32 dual model: RT-4 and ECV-304, which represented differentiated (G1) and poorly 33 differentiated (G3) BCa. We designed specific siRNA for down-regulation of 34 OP18 in both cell lines. Phenotypes were characterized by cell viability, 35 proliferation, and expression of apoptosis-related genes. Besides, sensitivity to 36 cisplatin treatment was evaluated. 37 Results: 38 Analysis of urine samples from patients with urothelial BCa revealed a significant 39 correlation of the RNA-ratio oncoprotein 18:uroplakin 1A with bladder cancer. 40 High urinary ratios were mainly found in moderately to poorly differentiated 41 tumors (grade G2-3) that were muscle invasive (stage T2-3), whereas samples 42 from patients with more differentiated non-invasive BCa (G1) showed low 43 OP18:UPK1A RNA ratios. Down-regulation of OP18 expression in ECV-304 44 shifted its phenotype towards G1 state. Further, OP18-directed siRNA induced 45 apoptosis and increased chemo-sensitivity to cisplatin. 46 Conclusions: 3 47 This study provides conclusive experimental evidence for the link between OP18-48 derived RNA as a diagnostic marker for molecular staging of BCa in non-invasive 49 urine-based diagnostics and the patho-mechanistic role of OP18 suggesting this 50 gene as a therapeutic target. 4 52 1 INTRODUCTION 53 54 The treatment of bladder cancer (BCa) depends on its stage. While non-muscle 55 invasive forms of BCa can be removed by TUR-B of tumor tissue and its 56 recurrence can be treated by immunotherapy with intra-vesicular delivery of 57 attenuated Bacillus Calmette-Guérin (BCG) or intra-vesical chemotherapy, 58 muscle-invasive tumor forms demand more aggressive strategies. Chemotherapy 59 includes platinum-based drugs like cis-diamminedichloridoplatinum(II), 60 (henceforth referred to as cisplatin), as one of the standard chemotherapeutic 61 agents for the treatment of metastatic BCa [1, 2]. 62 The efficacy of a multiplicity of chemotherapeutic agents including cisplatin is 63 often substantially decreased since BCa tumors frequently develop a drug-or 64 multiple drug-resistance (MDR) mechanisms [3, 4]. Drug-resistant cells show, 65 amongst others, an over-expression of anti-apoptotic genes [4]. Hence, the 66 identification of new molecular targets and alternative classes of drugs, including 67 oligonucleotide-based medications [5, 6], is crucial for the improvement of 68 survival rates of patients with advanced BCa. There is a high clinical interest in 69 objective and more accurate ways of tumor classification that may replace tissue-70 based histopathological staging. Innovative diagnostic approaches are 71 increasingly based on the non-invasive monitoring of BCa-specific tumor markers 72 in urine. Promising markers for bladder cancer had been based on RNA such as 73 microRNAs and also sequences of cellular mRNAs [7-9]. Further, we showed that 74 analysis of the RNA composition in whole urine of BCa patients reveals specific 5 75 and sensitive RNA-based tumor markers including ETS2 and uPA [10] as well as 76 microRNAs [11]. 77 In this study, we aimed to investigate whether differentially detectable RNAs 78 in whole urine of BCa patients provide improved tumor markers per se. Further, 79 we asked whether those RNA markers might display aberrant mRNA expression 80 (of OP18) in malignant cells. We used two different BCa cell culture models to 81 evaluate a possible involvement of OP18 gene expression in the tumorigenesis: 82 The human cell lines ECV-304 [12-14] and RT-4 [15], representing well (G1) and 83 poorly differentiated (G3) tumor states, respectively. To test whether model-based 84 G1/G3-related phenotypes were in line with our results in liquid biopsies, we 85 quantified RNA and protein levels of OP18 and performed several proliferation 86 and cell viability assays under siRNA mediated suppression of OP18 mRNA. We 87 also analyzed the influences of OP18 on apoptotic genes and chemo-sensitivity 88 of G3 cells. 6 90 2 MATERIALS AND METHODS 91 92 2.1 Clinical samples and preparation of RNAs 93 This study was approved by the local ethical research committee in Lübeck. All 94 urine samples were obtained with written informed consents of the participants. 95 Tumor grading was determined by urinary bladder cystoscopy. In addition to 96 biopsy, urine cytology was performed. All tumors identified were completely 97 resected and classified pathologically according to the World Health Organization 98 1973 grading and staging system. For investigation of urinary OP18 and 99 uroplakin 1A (UPK1A) RNA levels, spontaneously voided urine of 113 donors 100 was collected: 61 BCa patients (male:female, 3:1; G1 pTa, n = 13; G2+G3 101 pTa+pTis, n = 19; G2+G3 pT1, n = 12; G2+G3 pT2+pT3, n = 17; median age, 71 102 years), 37 healthy volunteers (male:female, 2:1; median age, 71 years), and 15 103 patients with infections of the urinary tract (male:female, 1:7; median age, 55 104 years). Urine samples were stabilized immediately as described recently [11]. 105 Total RNA from cells was prepared using the RNeasy Mini kit (Qiagen, Hilden, 106 Germany), and urinary RNA was isolated using the RNeasy Midi Kit (Qiagen, 107 Hilden, Germany), except for the lysis buffer described above which was used 108 instead of buffer "RLT". RNA was eluted twice with 160 µl H 2 O and then 109 lyophilized. Pellets were resolved in 20 µl H 2 O, and the quality of RNA was 110 assessed by agarose gel electrophoresis (using 1 µg/ml ethidium bromide). 111 Urinary RNA extract (10 µl) or 400 ng total RNA from cells were used for cDNA 112 synthesis and minus reverse transcriptase (non-RT) reaction. 7 113 114 2.2 cDNA synthesis 115 Reverse transcription was performed in a total volume of 20 µl with RNA extract 116 (10 µl), and 300 ng random hexamer primer (Invitrogen, Paisley, UK) following 117 the manufacturer's instructions for SuperScript III™ driven reverse transcription 118 (Invitrogen, Paisley, UK), despite a little increase of time and temperature for the 119 denaturation 75°C and 10 min. 120 121 2.3 Quantitative PCR (qPCR) and data analysis 122 Primers and TaqMan® probes were designed using Primer Express® software 123 version 2.0 (Applied Biosystems, Darmstadt, Germany) or Primer3 software 124 (Steve Rozen, Whitehead Institute for Biomedical Research, Cambridge, UK) and 125 were purchased from Metabion (Martinsried, Germany) and Eurogentec (Seraing, 126 Belgium), respectively. Primer sequences were checked for homology using the 127 Blast software (www.ncbi.nlm.nih.gov/BLAST). Amplicon characteristics and
159 2.5 Design and validation of siRNAs
160 Two small interfering RNAs targeting OP18 mRNA were designed in silico 161 according to a systematic computational analysis of local target mRNA structures 162 as described previously [16] . An extensive BLAST search indicated that both 163 siRNA sequences were target-specific. Nucleotide sequences of the effective 164 siRNA and a scrambled control siRNA without homology to human sequences 165 are shown in the S2 Table. For the annealing of RNA strands (from IBA 166 Goettingen, Germany), 20 µM of the sense and antisense strand, respectively, 167 was denaturated in buffer (50 mmol/l potassium acetate, 1 mmol/l magnesium 168 acetate, 15 mmol/l HEPES (pH 7.4)) at 90°C for 2 min followed by an annealing 169 step at 37°C for 1 h. For transfection of siRNA, cells were seeded into tissue 170 culture plates (12-well: 5 x 10 4 ECV-304 cells or 8 x 10 4 RT-4 cells; 96-well plates: 177 days, or in 96-well for 4 days) 3-5 x 10 3 ECV-304 cells or 1 x 10 4 RT-4 cells were 178 seeded in 12-well plates with 1 ml of culture medium or 0.1 ml in 96-well plates, 179 respectively. After 18-24 h, cells were transfected with siRNAs as described 180 above. Every 2 days, 500 µl for 12-well (and 50 µl for 96-well) plates of culture Fig. 1 B) . To compare OP18 to UPK1A-mRNA ratios of three or more patient 250 groups, the Kruskal-Wallis test (H-test) and for two different patient groups the 251 unpaired Mann-Whitney-U test was used. For all statistical tests, two-sided P 252 values ≤ 0.05 were considered as statistically significant. 268 RNA levels of OP18 and UPK1A, respectively, and suggested the validity of this 269 cell-based system to study the role of OP18 for malignant cell proliferation of 270 bladder cancer ( Fig. 1 B and C) . 279 moderate down-regulation of OP18 to levels of 31% at 24 h after transfection in 280 RT-4 ( Fig. 2 A) . 
294
295 Thereafter, OP18 mRNA expression increased to the level detected in control-296 siRNA treated RT-4 cells. In contrast, in ECV-304 cells, the OP18 expression was 297 inhibited efficiently to levels of approximately 2% of relative expression (Fig. 2 B) .
298 At the OP18 protein level, suppression was investigated for ECV-304 only (Fig. 2 299 C). A substantial decrease of OP18 protein signal was observed at days 2, 3, and 300 4 after transfection which relates to 15%, 4%, and 7% suppression, respectively 301 (as compared to control siRNA). 
